Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Tongji University · Shanghai Pulmonary Hospital · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
4,094
total citations
- FWCI
- 232.59
- Percentile
- 100%
- References
- 25
Citations per year
Authors
24- CZCaicun ZhouCorresponding
Tongji University, Shanghai Pulmonary Hospital
- YWYi‐Long Wu
Guangdong General Hospital, Guangdong Academy of Medical Sciences
- GCGongyan Chen
Harbin Medical University, Third Affiliated Hospital of Harbin Medical University
- JFJifeng Feng
Jiangsu Cancer Hospital
- XLXiao-Qing Liu
Academy of Military Medical Sciences
Topics & keywords
Topics
Keywords
- Medicine
- Erlotinib
- Internal medicine
- Lung cancer
- Gemcitabine
- Oncology
- Tolerability
- Carboplatin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.